Alzheimer's News Today Home | Alzheimer's News Today
Nov 4, 2024 · Dalzanemdor halted for Alzheimer’s; fails to boost cognitive function. Sage Therapeutics plans to stop developing dalzanemdor (SAGE-718) for Alzheimer’s disease after the treatment failed to meet the main goal of improving cognitive function in a Phase 2 study in patients with mild cognitive impairment or mild dementia.
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’s
Sep 22, 2023 · Treatment for two years with oral ALZ-801 (valiltramiprosate) sustained cognition and lowered levels of disease-related biomarkers in people with early Alzheimer’s disease carrying one or two copies of the disease-linked APOE4 genetic variant.
News Archives - Alzheimer's News Today
Alzheimer’s in people younger than 65 linked to night light exposure. Higher exposure to outdoor light at night may increase the risk of developing Alzheimer’s disease, especially in people younger than 65, according to a study that drew on Medicare records and …
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Feb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.
About Us - Alzheimer's News Today
Alzheimer’s News Today is a digital platform intended to provide the Alzheimer’s disease community with the most recent news and information on the disease, as well as first-hand community perspectives from our patient and caregiver columnists.
Namenda (Memantine) - Alzheimer's News Today
Namenda (memantine) is approved to treat moderate to severe Alzheimer’s, and works by preventing excessive calcium from entering and damaging brain cells.
Subscribe – Alzheimer's News Today
Publishing the web’s most comprehensive platform for Alzheimer’s News, columns, patient perspectives and resources requires a significant investment of resources each month for our talented and growing staff of PhD researchers, veteran journalists, talented social media team, and patient columnists.
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
Mar 14, 2023 · Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.
Aricept (Donepezil) - Alzheimer's News Today
Aricept (donepezil) is an approved oral medication that treats the symptoms of dementia caused by Alzheimer’s disease by improving cognition and function.
In early Alzheimer’s, Anavex 2-73 slows cognitive decline...
Sep 15, 2023 · The new analyses showed patients on Anavex 2-73 saw significantly greater score reductions in the ADAS-Cog (by 1.78 points) and CDR-SB (by 0.46 points) throughout the study than those on a placebo. The findings reflect a slowing of cognitive declines with the therapy.